His responsibilities will consist of overseeing 1Globe Biomedical’s clinical and regulatory affairs, product development team and offer support to plan and design and implement clinical trials and studies.
Dr. Parker joins 1Globe Biomedical from a Chinese start-up where he held a series of director-level clinical development roles and he led clinical development initiatives for innovating and increasing the efficiency of the its cardiovascular portfolio.
1Globe Biomedical’s Executive Vice President commented on Dr. Parkers appointment saying “We are delighted to welcome a professional of Dr. Parker’s ability and knowledge. His experience in cardiovascular therapy is of high importance to us and he will offer a lot to 1Globe Biomedical to become a pioneer in this industry.”
Dr. Thomas Parker earned his Bachelor’s in Molecular Biology from the University College London (UCL) and then went on to complete his Doctorate in Neuroscience from the Karolinska Institute of Medicine in Sweden, before finally completing his PhD in Bioinformatics from the Imperial College in London.
About Us – 1Globe Biomedical
1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.